rivaroxaban


Also found in: Medical, Wikipedia.
Related to rivaroxaban: Apixaban, Pradaxa, Dabigatran
Translations

rivaroxaban

n rivaroxabán m
References in periodicals archive ?
Rivaroxaban monotherapy is non inferior to combination therapy in patients with atrial fibrillation and stable coronary artery disease either not requiring intervention or more than one year after revascularisation.
Case for rivaroxaban and aspirin for pad gets stronger !-- -- Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS trial, which included more than 7,000 patients whose primary diagnosis at study entry was stable PAD.
Portola Pharmaceuticals announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants apixaban and rivaroxaban and the ability of four-factor prothrombin complex concentrate to correct inhibition of thrombin generation, compared with warfarin anticoagulation reversal by 4F-PCC.
Rivaroxaban (Xarelto[R]; Bayer Schering Pharma AG, Germany) is an oral anticoagulant that acts as a direct factor Xa inhibitor.
PATIENTS RECEIVING ORAL anticoagulant treatment had the lowest risk of gastrointestinal bleeding when taking apixaban, compared with rivaroxaban, dabigatran, and warfarin, according to a recent study.
It is claimed to be the first and only antidote indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is required due to life-threatening or uncontrolled bleeding.
CHICAGO--Apixaban outperformed two other direct-acting oral anticoagulants, dabigatran and rivaroxaban, by preventing more thrombotic events and not causing as many major bleeds in patients with atrial fibrillation who were at least 80 years old.
Summary: The oral factor Xa inhibitor rivaroxaban has shown a favorable wellbeing and efficacy profile as compared to the well known anticoagulant drug warfarin for the prevention and treatment of thromboembolic disorders.
19, 2018 (HealthDay News) -- Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept.
Recientemente, la Comision Federal para la Proteccion contra Riesgos Sanitarios (Cofepris) aprobo dos nuevos usos terapeuticos para Rivaroxaban (Xarelto), innovador anticoagulante ya disponible en el sector salud que contribuira a reducir en los pacientes el riesgo de recurrencias de la enfermedad tromboembolica venosa, asi como enfermedad vascular cerebral en aquellos pacientes con fibrilacion auricular no valvular y que han sido sometidos a una intervencion coronaria con colocacion de stent.
Rivaroxaban is a direct, antithrombin-independent factor Xa inhibitor, which inhibits not only free factor Xa, but also clot-bound factor Xa and the prothrombinase complex.
Rivaroxaban's onset of action is 30 minutes, faster than the 36-72 hours for warfarin (which requires overlap with heparin therapy).